Global InformationDonislecel information
| Clinical data | |
|---|---|
| Trade names | Lantidra |
| Other names | donislecel-jujn |
| License data |
|
| Routes of administration | Islet cell transplantation via intravenous infusion[1][2] |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG |
|
Donislecel, sold under the brand name Lantidra, is a cellular therapy medication used for the treatment of type 1 diabetes.[3][5] Donislecel is an allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells.[5] Donislecel is administered as a single infusion into the hepatic (liver) portal vein.[5]
The most common adverse reactions include nausea, fatigue, anemia, diarrhea, and abdominal pain.[5]
Donislecel was approved for medical use in the United States in June 2023.[3][5]
- ^ "Archived copy". Food and Drug Administration. Archived from the original on 9 December 2022. Retrieved 29 June 2023.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Archived copy". Food and Drug Administration. Archived from the original on 19 May 2021. Retrieved 29 June 2023.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ a b c "Lantidra- donislecel solution". DailyMed. 10 July 2023. Retrieved 28 August 2023.
- ^ "Lantidra". U.S. Food and Drug Administration (FDA). 28 June 2023. Archived from the original on 5 July 2023. Retrieved 5 July 2023.
- ^ a b c d e f Cite error: The named reference
FDA PR 20230628was invoked but never defined (see the help page).